Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590889 · ClinicalTrials.gov registry record · NA
Artificial Valve Endocarditis Reduction Trial
A NA study, sponsored by Abbott Medical Devices.
- Terminated
- Registry status
- NA
- Development phase
- 807
- Enrollment target
NCT00590889: Clinical Trial NA study, sponsored by Abbott Medical Devices.
NCT00590889 is a NA study that was terminated before completion, run by Abbott Medical Devices. The registered enrollment target is 807 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00590889, a NA study, was terminated before completion, sponsored by Abbott Medical Devices.
- TERMINATED
- Registry status
- NA
- Development phase
- 807 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether the Silzone coated sewing cuff reduces the incidence of prosthetic valve endocarditis (PVE).
Primary Outcome
Patient response to treatment with the Silzone™ treated valve will be evaluated based upon the incidence of early and late PVE (prosthetic valve endocarditis) in the treatment group vs. the control group.
Interventions
- DEVICE Artificial Mechanical Heart Valve
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 807 participants |
| Start Date | 1998-07 |
| Est. Completion | 2014-09 |
| Phase | NA |
Why NCT00590889 stopped before completion
NCT00590889 is an interventional study that assigns participants to a tested intervention. The registered 807 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (43% lower).
The record links to 0 conditions, and to 1 intervention - of which Artificial Mechanical Heart Valve is the first listed.
NCT00590889 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00590889 about?
NCT00590889 is a clinical study titled "Artificial Valve Endocarditis Reduction Trial". The purpose of this study is to investigate whether the Silzone coated sewing cuff reduces the incidence of prosthetic valve endocarditis (PVE).
What is the current status of trial NCT00590889?
This trial is currently terminated. It is a NA study. The enrollment target is 807 participants. The study started on 1998-07. Estimated completion is 2014-09.
What interventions are being tested in trial NCT00590889?
The interventions under investigation include: Artificial Mechanical Heart Valve (DEVICE).
Who is sponsoring clinical trial NCT00590889?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00590889's enrollment target sits among peer trials
807 134th of 2000 higher than 1,867 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia